| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Current assets | | | | | | | | |
| Cash and cash equivalents | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 |
| Accounts receivable | 0.2 | | | | | | | |
| Prepaid expenses and other assets | 0.1 | | | | | | | |
| Income taxes refundable | 0.0 | | | | | | | |
| Loan receivable from Emergence Global Enterprises Inc. - related party | | 0.0 | | | | | | |
| Total current assets | 0.5 | 0.0 | 0.0 | 0.4 | 0.3 | 0.1 | 0.0 | 0.2 |
| |
| Other assets | | | | | | | | |
| Operating lease right-of-use assets | 0.1 | | | | | | | |
| Other receivable | | 0.1 | 0.4 | 0.4 | 0.2 | | | |
| Note receivable - CEN Biotech Ukraine LLC - related party | 0.0 | 0.0 | | | | | | |
| Advances to CEN Biotech Ukraine LLC - related party | 1.3 | 1.2 | | | | | | |
| Property and equipment, net | 0.1 | | 0.1 | 0.2 | 0.0 | 0.0 | | |
| Deferred income taxes | 0.0 | | | | | | | |
| Intangible assets, net | -5.1 | -5.0 | 5.4 | 5.8 | 6.2 | 6.7 | | |
| Goodwill | 1.3 | | | | | | | |
| Total assets | 8.4 | 6.3 | 7.3 | 7.3 | 9.0 | 8.4 | 8.3 | 8.5 |
| |
| Current liabilities | | | | | | | | |
| Accounts payable | 0.4 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | |
| Accounts payable – related parties | 0.1 | 0.0 | | | 0.0 | 0.1 | 0.1 | |
| Loans payable | 1.7 | 0.5 | 10.1 | 10.1 | 10.0 | 10.0 | | |
| Loans payable – related parties | 2.7 | 1.4 | 1.4 | | | | | |
| Convertible notes payable, net of unamortized discount | 0.6 | 6.7 | 5.2 | 3.6 | 1.5 | | | |
| Convertible notes payable, net of unamortized discount - related parties | 0.2 | 2.6 | | | | | | |
| Accrued interest | 1.4 | 1.1 | 9.6 | 6.9 | 4.5 | 2.6 | 1.2 | 0.1 |
| Accrued interest – related parties | 1.9 | 1.6 | | | | | | |
| Operating lease liabilities | 0.1 | 0.0 | | | | | | |
| Governmental assistance payable | 0.1 | | | | | | | |
| Accrued expenses | 0.6 | 0.6 | 0.6 | 0.4 | 0.3 | 0.8 | 0.6 | 0.2 |
| Total current liabilities | 9.9 | 14.7 | 30.9 | 24.4 | 20.0 | 14.7 | 13.5 | 11.2 |
| Operating lease liabilities, less current portion | 0.2 | 0.1 | | | | | | |
| CEBA loan payable | 0.0 | | | | | | | |
| Total liabilities | 10.1 | 16.3 | 32.8 | 28.6 | 28.0 | 22.5 | 14.1 | 11.9 |
| |
| Commitments and contingencies (Notes 4, 11, 12, 18, 19, 24, and 25) | | | | | | | | |
| Shareholders’ deficit | | | | | | | | |
| Common stock; unlimited authorized shares; 63 | | | | | | | 0.0 | 0.0 |
| Additional paid-in capital | 44.3 | 17.1 | 15.8 | 14.4 | 9.1 | 0.0 | | |
| Accumulated deficit | -46.0 | -27.1 | -41.3 | -35.7 | -28.1 | -14.0 | -5.8 | -3.4 |
| Accumulated other comprehensive loss | 0.0 | | | | | | | |
| Total shareholders’ deficit | -1.7 | -10.0 | -25.5 | -21.3 | -19.0 | -14.0 | -5.8 | -3.4 |
| Total liabilities and shareholders’ deficit | 8.4 | 6.3 | 7.3 | 7.3 | 9.0 | 8.4 | 8.3 | 8.5 |